vs
CytomX Therapeutics, Inc.（CTMX）与LIGHTPATH TECHNOLOGIES INC（LPTH）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是LIGHTPATH TECHNOLOGIES INC的1.1倍（$18.7M vs $16.4M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -57.5%，领先56.7%），LIGHTPATH TECHNOLOGIES INC同比增速更快（120.2% vs -25.7%），LIGHTPATH TECHNOLOGIES INC自由现金流更多（$2.0M vs $-15.8M），过去两年LIGHTPATH TECHNOLOGIES INC的营收复合增速更高（45.7% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
LightPath Technologies Inc是一家精密光学组件及组件生产商，主营非球面透镜、红外光学器件、光纤产品等，服务工业自动化、航空航天、国防、医疗成像、电信等领域的全球客户，提供标准及定制化光学解决方案。
CTMX vs LPTH — 直观对比
损益表 — Q2 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $16.4M |
| 净利润 | $-154.0K | $-9.4M |
| 毛利率 | — | 36.8% |
| 营业利润率 | -6.9% | -52.6% |
| 净利率 | -0.8% | -57.5% |
| 营收同比 | -25.7% | 120.2% |
| 净利润同比 | 97.6% | -260.1% |
| 每股收益（稀释后） | — | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $16.4M | ||
| Q3 25 | — | $15.1M | ||
| Q2 25 | $18.7M | $12.2M | ||
| Q1 25 | $50.9M | $9.2M | ||
| Q4 24 | $38.1M | $7.4M | ||
| Q3 24 | $33.4M | $8.4M | ||
| Q2 24 | $25.1M | $8.6M | ||
| Q1 24 | $41.5M | $7.7M |
| Q4 25 | — | $-9.4M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | $-154.0K | $-7.1M | ||
| Q1 25 | $23.5M | $-3.6M | ||
| Q4 24 | $18.9M | $-2.6M | ||
| Q3 24 | $5.7M | $-1.6M | ||
| Q2 24 | $-6.5M | $-2.4M | ||
| Q1 24 | $13.8M | $-2.6M |
| Q4 25 | — | 36.8% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 22.0% | ||
| Q1 25 | — | 29.1% | ||
| Q4 24 | — | 26.0% | ||
| Q3 24 | — | 33.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 20.9% |
| Q4 25 | — | -52.6% | ||
| Q3 25 | — | -16.6% | ||
| Q2 25 | -6.9% | -38.0% | ||
| Q1 25 | 44.4% | -36.3% | ||
| Q4 24 | 46.4% | -33.5% | ||
| Q3 24 | 12.3% | -16.4% | ||
| Q2 24 | -33.7% | -25.6% | ||
| Q1 24 | 28.1% | -33.6% |
| Q4 25 | — | -57.5% | ||
| Q3 25 | — | -19.2% | ||
| Q2 25 | -0.8% | -57.8% | ||
| Q1 25 | 46.2% | -39.1% | ||
| Q4 24 | 49.6% | -35.2% | ||
| Q3 24 | 17.2% | -19.3% | ||
| Q2 24 | -26.0% | -27.3% | ||
| Q1 24 | 33.3% | -33.7% |
| Q4 25 | — | $-0.20 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $-0.44 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $73.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $77.9M |
| 总资产 | $175.1M | $148.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $73.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | $4.9M | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $535.0K | ||
| Q1 24 | — | $599.4K |
| Q4 25 | — | $77.9M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | $119.9M | $15.6M | ||
| Q1 25 | $25.0M | $15.7M | ||
| Q4 24 | $-456.0K | $26.7M | ||
| Q3 24 | $-23.5M | $29.4M | ||
| Q2 24 | $-31.2M | $30.2M | ||
| Q1 24 | $-31.7M | $31.7M |
| Q4 25 | — | $148.6M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | $175.1M | $81.5M | ||
| Q1 25 | $98.5M | $81.4M | ||
| Q4 24 | $120.5M | $45.8M | ||
| Q3 24 | $139.0M | $48.4M | ||
| Q2 24 | $159.2M | $48.1M | ||
| Q1 24 | $184.7M | $49.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $2.8M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $2.0M |
| 自由现金流率自由现金流/营收 | -84.6% | 12.0% |
| 资本支出强度资本支出/营收 | 0.1% | 5.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $-6.3M |
8季度趋势，按日历期对齐
| Q4 25 | — | $2.8M | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-15.8M | $-2.6M | ||
| Q1 25 | $-21.0M | $-3.2M | ||
| Q4 24 | $-19.9M | $-737.4K | ||
| Q3 24 | $-20.7M | $-1.7M | ||
| Q2 24 | $-19.5M | $64.7K | ||
| Q1 24 | $-26.0M | $-394.2K |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-15.8M | $-3.3M | ||
| Q1 25 | $-21.2M | $-3.7M | ||
| Q4 24 | $-20.0M | $-817.8K | ||
| Q3 24 | $-20.7M | $-1.8M | ||
| Q2 24 | $-19.6M | $-225.5K | ||
| Q1 24 | $-26.2M | $-802.5K |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | -84.6% | -27.3% | ||
| Q1 25 | -41.6% | -40.0% | ||
| Q4 24 | -52.5% | -11.0% | ||
| Q3 24 | -62.1% | -21.2% | ||
| Q2 24 | -78.2% | -2.6% | ||
| Q1 24 | -63.1% | -10.4% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | 0.1% | 5.6% | ||
| Q1 25 | 0.2% | 4.6% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.1% | 0.9% | ||
| Q2 24 | 0.4% | 3.4% | ||
| Q1 24 | 0.3% | 5.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LPTH
| Other | $7.9M | 48% |
| Infrared Components | $5.0M | 31% |
| Visible Components | $3.4M | 21% |
